Blueberries Medical Corp. (C:BBM)
Business Focus: Cannabis Product Retailers
| Sector: Consumer Non-Cyclicals | Industry: Drug Retailers |
| Company Contact | |
| Address: | 82 Richmond Street East TORONTO ON M5C 1P1 |
| Tel: | N/A |
| Website: | https://www.blueberriesmed.com |
| IR: | See website |
| Key People | ||
| N/A | ||
| Business Overview |
| Blueberries Medical Corp. is a Canada-based company, which is a licensed producer of psychoactive and non-psychoactive cannabis by-products in Colombia. The Company is engaged in the growth, cultivation, and development of medicinal cannabis and related products with operations in Colombia. The Company is focused on processing and supplying medicinal-grade Cannabis oil extracts, medical flowers, and related products. It is developing and commercializing a range of cannabis-derived ingredients, including high and low tetrahydrocannabinol (THC), cannabidiol (CBD), and other cannabinoids. The Company's subsidiaries include Blueberries Research Corporation (BRC), Blueberries SAS (BBSAS), Centro De Desarrollo e Investigacion (CDIBBSAS), BBV Labs Inc. (BBV Labs.) and SATIN S.A.S. (SATIN). Blueberries SAS is a licensed producer and distributor of medicinal Cannabis and Cannabis-derived products in Colombia. |
| Financial Overview |
| For the nine months ended 30 September 2023, Blueberries Medical Corp revenues increased 28% to C$229K. Net loss decreased 15% to C$1.3M. Revenues reflect Colombia segment increase of 58% to C$229K. Lower net loss reflects Depreciation and amortization decrease of 62% to C$115K (expense), Salary and benefits decrease of 46% to C$202K (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.01. |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $9.90M as of Sep 30, 2023 |
| Annual revenue (TTM): | $0.29M as of Sep 30, 2023 |
| EBITDA (TTM): | -$1.13M as of Sep 30, 2023 |
| Net annual income (TTM): | -$1.25M as of Sep 30, 2023 |
| Free cash flow (TTM): | -$1.37M as of Sep 30, 2023 |
| Net Debt Last Fiscal Year: | $1.01M as of Sep 30, 2023 |
| Shares outstanding: | 399,025,152 as of Dec 29, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
